A New Era in Medical Weight Management Inspired by growing consumer interest in GLP-1s, medications like tirzepatide and semaglutide represent a more effective approach to health management
Hives (urticaria) are classified as an uncommon adverse effect of Wegovy, affecting between 1 in 100 and 1 in 1,000 patients according to the Summary of Product Characteristics
The 55% liver fat reduction observed in NASH patients reflects this pathway
Another GLP-1/GIP/glucagon receptor triagonist known as retatrutide (previously LY3437943) was developed by Eli Lilly in 2022 leading to weight loss, reduced fat mass, decreased blood glucose and insulin levels in obese mice, which was attributed to increased energy expenditure and lipid oxidation [62]
Small, consistent changeslike eating enough protein, choosing fibre-rich foods, and including healthy fatscan make a meaningful difference in how satisfied you feel after eating
PloS One (2014) 9:e94433